All In Biotech

Drug Trial Radar · NCT06812754

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

A Phase 2, Randomized, Placebo-controlled, 12-week, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Chinese Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Mar 10, 2025

Primary completion

Feb 11, 2026

Study completion Mar 5, 2026

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. The goal of this study is to confirm if fezolinetant helps reduce hot flashes in Chinese women going through menopause. This study will also confirm the safety of fezolinetant and how well the women cope with (tolerate) the treatment. The women will take 1 tablet of the study medicine either fezolinetant or placebo once a day for up to 12 weeks. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes and night sweats. The women will record this information before, during and after taking the study treatment. During the study, the women will visit the study clinic several times. At each visit they will be asked if they had any medical problems. The women will have general safety checks. At some visits, a breast ultrasound (mammogram), cervical smear, and ultrasound of the womb (uterus) may be done. The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or placebo).

Conditions

  • Hot Flashes

Interventions

  • FezolinetantDrug

    oral

  • PlaceboDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in the frequency of moderate to severe Vasomotor Symptoms (VMS) from baseline to week 12Time frame: Baseline to Week 12

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Capital Medical University (CMU) - Beijing Shijitan Hospital

    Beijing, Beijing Municipality, China

  • Capital Medical University - Beijing Obstetrics and Gynecology Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Guangzhou Medical University - The Third Affiliated Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Shenzhen Maternal & Child Health Hospital

    Shenzhen, Guangdong, China

  • Guangxi Medical University (GXMU) - Liuzhou Renmin Hospital

    Liuzhou, Guangxi, China

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, China

  • Hainan Women and Children's Medical Center

    Haikou, Hainan, China

  • The second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Hunan Provincial Maternal and Child Health Care Hospital

    Changsha, Hunan, China

  • Xiangya Hospital, Central South University

    Zhuzhou, Hunan, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, China

  • Southeast University, ZhongDa Hospital

    Nanjing, Jiangsu, China

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, Jiangxi, China

  • Jilin Province FAW General Hospital

    Changchun, Jilin, China

  • Jinan Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

  • Shandong Provincial Hospital

    Jinan, Shandong, China

  • Shanghai First Maternity and Infant Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Woman and Children Hospital

    Taiyuan, Shanxi, China

  • The First hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Chengdu Women's and Children's Central Hospital

    Chengdu, Sichuan, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.